Advertisement
U.S. markets close in 5 hours 49 minutes
  • S&P 500

    5,251.16
    +2.67 (+0.05%)
     
  • Dow 30

    39,760.76
    +0.68 (+0.00%)
     
  • Nasdaq

    16,387.33
    -12.19 (-0.07%)
     
  • Russell 2000

    2,119.59
    +5.24 (+0.25%)
     
  • Crude Oil

    82.36
    +1.01 (+1.24%)
     
  • Gold

    2,227.80
    +15.10 (+0.68%)
     
  • Silver

    24.71
    -0.04 (-0.17%)
     
  • EUR/USD

    1.0812
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2642
    +0.0004 (+0.03%)
     
  • USD/JPY

    151.2650
    +0.0190 (+0.01%)
     
  • Bitcoin USD

    71,016.17
    +1,848.82 (+2.67%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,960.86
    +28.88 (+0.36%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study

  • Avrobio Inc (NASDAQ: AVRO) has reported positive data from the ongoing Phase 2 FAB-GTi Phase 1/2 trial evaluating AVR-RD-01, an ex vivo lentiviral gene therapy for Fabry disease. 100% reduction, or complete clearance, of the toxic substrate in the kidney biopsy, was observed in the first patient dosed.

  • The company also announced six-month data from the first patient dosed in the Phase 1/2 trial of AVR-RD-02, an ex vivo lentiviral gene therapy for Gaucher disease type 1, showing substantial improvement over pre-gene therapy enzyme replacement therapy baseline in key biomarkers at six months post-gene therapy. Plasma chitotriosidase levels decreased 49%, and toxic metabolite lyso-Gb1 levels dropped 44% in the first patient at six months post-gene therapy, compared to the patient's pre-gene therapy ERT baseline levels.

  • Additionally, preliminary data from the investigator-sponsored Phase 1/2 trial of AVR-RD-04 showed that all three cystinosis patients demonstrated strong data across multiple measures, including substantial improvement in photophobia in the first patient 12 months post-gene therapy. All patients remained off cysteamine pills, and eye drops, with trial enrollment completion expected this year.

  • The Investor and analyst presentation is scheduled today at 8 a.m. ET.

  • Price Action: AVRO jumped 19.6% at $20.46 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement